Use of healthcare reimbursement data to monitor bacterial sexually transmitted infection testing in France, 2006 to 2020.
COVID-19 impact
STI
chlamydia infection
gonorrhoea
syphilis
testing
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
entrez:
30
9
2022
pubmed:
1
10
2022
medline:
4
10
2022
Statut:
ppublish
Résumé
BackgroundDiagnoses of bacterial sexually transmitted infections (STIs) have increased in France since the 2000s. The main strategy to control STI transmission is recommending/facilitating access to condom use, testing, and antibiotic treatments.AimThis study analyses the evolution of STI testing in the private sector in France from 2006 to 2020.MethodsNational health insurance reimbursement data were used to determine numbers and rates of individuals aged ≥ 15 years tested for diagnoses of chlamydia, gonorrhoea and syphilis in the private sector in France and to describe their evolution from 2006 to 2020.ResultsUpward tendencies in testing were observed from 2006 to 2019 for all three STIs. The highest testing rates were identified in people aged 25‒29-years old. The observed testing-increase from 2017 to 2019 was twice as high in young people (< 25 years old) as in older people. In 2019, chlamydia, gonorrhoea and syphilis testing rates were respectively 45.4 (+ 21% since 2017), 41.3 (+ 60%), and 47.2 (+ 22%) per 1,000 inhabitants. For all STIs combined, the number of tested individuals decreased by 37% between March and April 2020 during the first COVID-19 epidemic wave and lockdown in France.ConclusionImprovements found in STI testing rates may have resulted from better awareness, especially among young people and health professionals, of the importance of testing, following prevention campaigns. Nevertheless, testing levels remain insufficient considering increasing diagnoses. In 2020, the COVID-19 pandemic had a considerable impact on STI testing. Partner notification and offering diverse testing opportunities including self-sampling are essential to control STI epidemics particularly in exposed populations.
Identifiants
pubmed: 36177869
doi: 10.2807/1560-7917.ES.2022.27.39.2100618
pmc: PMC9524053
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : ErratumIn
Références
J Eur Acad Dermatol Venereol. 2016 Oct;30(10):e78-e79
pubmed: 26372738
Clin Infect Dis. 2018 Aug 16;67(5):676-686
pubmed: 29509889
AIDS. 2016 Sep 10;30(14):2251-2
pubmed: 27314179
BMC Public Health. 2021 Sep 7;21(1):1637
pubmed: 34493244
BMJ Open. 2018 Jul 23;8(7):e020336
pubmed: 30037863
Sex Transm Infect. 2021 Nov;97(7):550
pubmed: 33397798
Ann Dermatol Venereol. 2016 Nov;143(11):720-724
pubmed: 27773508
Sex Transm Infect. 2022 Feb;98(1):70
pubmed: 33653880
Euro Surveill. 2019 Jan;24(5):
pubmed: 30722812
APMIS. 2022 Jan;130(1):34-42
pubmed: 34758169
Rev Med Interne. 2015 Jun;36(6):411-7
pubmed: 25547954
Am J Prev Med. 2021 Sep;61(3):386-393
pubmed: 34020848
Euro Surveill. 2020 Nov;25(47):
pubmed: 33243354
Sex Transm Infect. 2022 Nov;98(7):537-538
pubmed: 34548415